CSBR vs IMVT vs CRL vs IQV

For growth investors, Champions Oncology, Inc.

(CSBR) is the stronger pick with 13. 5% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Champions Oncology, Inc. (CSBR) offers the better valuation at 18. 2x trailing P/E, making it the more compelling value choice. Analysts rate Immunovant, Inc. (IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Champions Oncology, Inc.

(CSBR) is the cheapest at 18. 2x versus IQVIA Holdings Inc. at 22. 8x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +84. 4%, compared to -46. 6% for Charles River Laboratories International, Inc. (CRL). Over 10 years, the gap is even starker: IMVT returned +190. 9% versus CSBR's +48. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Champions Oncology, Inc.

(CSBR) is the lower-risk stock at 0. 54β versus Charles River Laboratories International, Inc. 's 1. 44β — meaning CRL is approximately 169% more volatile than CSBR relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Champions Oncology, Inc.

(CSBR) is pulling ahead at 13. 5% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Champions Oncology, Inc. grew EPS 161. 1% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, CSBR leads at 5. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IQVIA Holdings Inc.

(IQV) is the more profitable company, earning 8. 3% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — CSBR leads at 47. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, IQVIA Holdings Inc.

(IQV) trades at 14. 0x forward P/E versus 16. 0x for Charles River Laboratories International, Inc. — 2. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IMVT: 57. 2% to $45. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Champions Oncology, Inc.

(CSBR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54)). Both have compounded well over 10 years (CSBR: +48. 6%, CRL: +114. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.